title: Chronic monoamine oxidase-B inhibitor treatment blocks monoamine oxidase-A enzyme activity.
abstract: Patients with Parkinson's disease receive selective irreversible monoamine oxidase (MAO)-B inhibitors, but their effects on MAO-A activity are not known during long-term application. We determined MAO-A inhibition in plasma samples from patients with MAO-B inhibitor intake or without MAO-B inhibitor treatment and from healthy controls. We detected a 70 % reduction of MAO-A activity in patients with MAO-B inhibitor therapy in comparison to the other groups. Our results suggest that treatment with MAO-B inhibitor may also influence MAO-A activity in vivo, when administered daily.
authors.affiliation: Hospital of Child and Adolescent Psychiatry, University of Zurich, Winterthurerstr. 180, Room L84/86, 8057, Zurich, Switzerland, jasmin.bartl@kjpdzh.ch.
authors.forename: Jasmin
authors.initials: J
authors.lastname: Bartl
authors.forename: Thomas
authors.initials: T
authors.lastname: Müller
authors.forename: Edna
authors.initials: E
authors.lastname: Grünblatt
authors.forename: Manfred
authors.initials: M
authors.lastname: Gerlach
authors.forename: Peter
authors.initials: P
authors.lastname: Riederer
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007189:Indans / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D008995:Monoamine Oxidase / Q000097:blood*; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000097:blood* / Q000188:drug therapy*
chemical_list: D007189:Indans; D008996:Monoamine Oxidase Inhibitors; C031967:rasagiline; D008995:Monoamine Oxidase; C579458:monoamine oxidase A, human